Omrix Biopharmaceuticals, Inc. Says Anti-Bleeding Product Shows Promise; Shares Rise

Oct 8 (Reuters) - Omrix Biopharmaceuticals Inc said an interim analysis of its experimental anti-bleeding product Fibrin Pad showed it was superior to an already approved product in stopping mild to moderate bleeding in a U.S. mid-stage trial.